Anna Simon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5335040/publications.pdf

Version: 2024-02-01

50276 30922 10,887 141 46 102 citations h-index g-index papers 145 145 145 10864 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery, 2012, 11, 633-652.	46.4	1,479
2	<i>Horror Autoinflammaticus</i> : The Molecular Pathophysiology of Autoinflammatory Disease. Annual Review of Immunology, 2009, 27, 621-668.	21.8	970
3	Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). Journal of Experimental Medicine, 2011, 208, 519-533.	8.5	749
4	IL-1Î ² Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	4.7	427
5	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
6	Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Medicine (United States), 2008, 87, 301-310.	1.0	344
7	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
8	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
9	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.9	239
10	Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Seminars in Arthritis and Rheumatism, 2007, 37, 137-148.	3.4	228
11	Schnitzler's syndrome: diagnosis, treatment, and followâ€up. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 562-568.	5.7	224
12	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
13	Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics, 2004, 75, 476-483.	4.7	190
14	Molecular analysis of MVK mutations and enzymatic activity in hyper-lgD and periodic fever syndrome. European Journal of Human Genetics, 2001, 9, 260-266.	2.8	182
15	Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9801-9806.	7.1	177
16	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
17	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
18	Beneficial response to interleukin 1 receptor antagonist in traps. American Journal of Medicine, 2004, 117, 208-210.	1.5	146

#	Article	IF	CITATIONS
19	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.9	145
20	Mevalonate kinase deficiency. Neurology, 2004, 62, 994-997.	1.1	142
21	On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases, 2011, 70, 2155-2158.	0.9	142
22	Effect of etanercept and anakinra on inflammatory attacks in the hyper-lgD syndrome: introducing a vaccination provocation model. Netherlands Journal of Medicine, 2005, 63, 260-4.	0.5	134
23	Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2006, 65, 542-544.	0.9	126
24	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120
25	Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R86-R98.	1.8	118
26	Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2015, 135, 561-564.e4.	2.9	115
27	Hereditary periodic fever and reactive amyloidosis. Clinical and Experimental Medicine, 2005, 5, 87-98.	3 . 6	111
28	<i>MEFV</i> mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.9	101
29	Fever of unknown origin. Clinical Medicine, 2015, 15, 280-284.	1.9	95
30	Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 1634-1638.	0.9	90
31	IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission. Journal of Allergy and Clinical Immunology, 2008, 121, 260-262.	2.9	86
32	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	1.9	84
33	Molecular Analysis of the Mevalonate Kinase Gene in a Cohort of Patients with the Hyper-IgD and Periodic Fever Syndrome: Its Application as a Diagnostic Tool. Annals of Internal Medicine, 2001, 135, 338.	3.9	81
34	Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology, 2006, 45, 269-273.	1.9	79
35	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	5 . 7	74
36	Strong induction of <scp>AIM</scp> 2 expression in human epidermis in acute and chronic inflammatory skin conditions. Experimental Dermatology, 2012, 21, 961-964.	2.9	71

#	Article	IF	CITATIONS
37	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70
38	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
39	Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC 4 â€related autoinflammatory disease, expansion of the phenotype. British Journal of Dermatology, 2017, 176, 244-248.	1.5	64
40	Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa. Ophthalmology, 2013, 120, 2697-2705.	5.2	56
41	A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. American Journal of Medicine, $2003,114,148-152.$	1.5	55
42	Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective. Clinical Immunology, 2016, 171, 12-17.	3.2	55
43	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	2.2	54
44	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
45	Successful canakinumab treatment identifies IL- \hat{l}^2 as a pivotal mediator in Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2011, 128, 1352-1354.	2.9	49
46	Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies. Genome Medicine, 2019, 11, 38.	8.2	49
47	Cholesterol Metabolism and Immunity. New England Journal of Medicine, 2014, 371, 1933-1935.	27.0	48
48	Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?. Seminars in Immunopathology, 2015, 37, 371-376.	6.1	47
49	Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-lgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 1221-6.	2.5	46
50	A Clinical Criterion to Exclude the Hyperimmunoglobulin D Syndrome (Mild Mevalonate Kinase) Tj ETQq0 0 0 rgBT	/Oyerlock	10 Tf 50 22
51	TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology, 2015, 54, 363-368.	1.9	45
52	The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. Arthritis Research and Therapy, 2015, 17, 187.	3.5	45
53	ATP-Induced IL-1β Specific Secretion: True Under Stringent Conditions. Frontiers in Immunology, 2015, 6, 54.	4.8	43
54	Variable expression and treatment of PAPA syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1168-1170.	0.9	42

#	Article	IF	CITATIONS
55	Hyper-IgD syndrome or mevalonate kinase deficiency. Current Opinion in Rheumatology, 2011, 23, 419-423.	4.3	42
56	Familial Mediterranean feverâ€"a not so unusual cause of abdominal pain. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 199-213.	2.4	41
57	Recurrent febrile syndromes—what a rheumatologist needs to know. Nature Reviews Rheumatology, 2009, 5, 249-256.	8.0	41
58	Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. American Journal of Medicine, 2001, 110, 313-316.	1.5	40
59	Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Netherlands Journal of Medicine, 2009, 67, 302-5.	0.5	40
60	Circulating galectin-3 in infections and non-infectious inflammatory diseases. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1605-1610.	2.9	38
61	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases,	0.9	38
62	2022, 81, 907-921. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology, 2008, 47, 1651-1654.	1.9	37
63	Dysregulation of innate immunity: hereditary periodic fever syndromes. British Journal of Haematology, 2009, 144, 279-302.	2.5	37
64	Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood, 2007, 109, 2416-2418.	1.4	36
65	Unexplained recurrent fever: when is autoinflammation the explanation?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 285-296.	5.7	35
66	Mastâ€cell interleukinâ€1β, neutrophil interleukinâ€17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. British Journal of Dermatology, 2015, 173, 448-456.	1.5	35
67	Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. Journal of Internal Medicine, 2004, 256, 247-253.	6.0	34
68	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. Journal of Autoimmunity, 2015, 62, 39-44.	6.5	33
69	Drosomycin-Like Defensin, a Human Homologue of <i>Drosophila melanogaster</i> Prosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	3.2	32
70	Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. Journal of Allergy and Clinical Immunology, 2017, 140, 873-875.e6.	2.9	29
71	Genetic Analysis as a Valuable Key to Diagnosis and Treatment of Periodic Fever. Archives of Internal Medicine, 2001, 161, 2491-2493.	3.8	27
72	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27

#	Article	IF	CITATIONS
73	Pseudothrombocytopenia: a report of a new method to count platelets in a patient with EDTA- and temperature-independent antibodies of the IgM type. European Journal of Haematology, 2002, 69, 243-247.	2.2	25
74	Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes. Molecular Medicine, 2011, 17, 363-368.	4.4	23
75	Pattern recognition receptors in infectious skin diseases. Microbes and Infection, 2012, 14, 881-893.	1.9	23
76	Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infectious Diseases, 2015, 15, 140.	2.9	23
77	Rheumatologic diseases as the cause of fever of unknown origin. Best Practice and Research in Clinical Rheumatology, 2016, 30, 789-801.	3.3	23
78	Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature. Frontiers in Pharmacology, 2017, 8, 342.	3.5	23
79	Referral of patients with fever of unknown origin to an expertise center has high diagnostic and therapeutic value. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 793-801.	0.5	22
80	Hot and hobbling with hives: Schnitzler syndrome. Clinical Immunology, 2006, 119, 131-134.	3.2	21
81	Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Frontiers in Immunology, 2019, 10, 1900.	4.8	21
82	Long-term prognosis, treatment, and outcome of patients with fever of unknown origin in whom no diagnosis was made despite extensive investigation. Medicine (United States), 2018, 97, e11241.	1.0	20
83	Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 115-119.	3.0	17
84	Lovastatin inhibits formation of AA amyloid. Journal of Leukocyte Biology, 2008, 83, 1295-1299.	3.3	17
85	Phenotypic diversity, disease progression, and pathogenicity of <scp><i>MVK</i></scp> missense variants in mevalonic aciduria. Journal of Inherited Metabolic Disease, 2021, 44, 1272-1287.	3.6	17
86	Cathepsin D activity protects against development of type AA amyloid fibrils. European Journal of Clinical Investigation, 2009, 39, 412-416.	3.4	16
87	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor–associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
88	Curation and expansion of Human Phenotype Ontology for defined groups of inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2022, 149, 369-378.	2.9	16
89	Pseudohypoparathyroidism type Ia Albright hereditary osteodystrophy: a model for research on G protein-coupled receptors and genomic imprinting. Netherlands Journal of Medicine, 2000, 56, 100-109.	0.5	14
90	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukinâ€1 Mediated Autoinflammatory Diseases: Cryopyrinâ€Associated Periodic Syndromes, Tumour Necrosis Factor Receptorâ€Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukinâ€1 Receptor Antagonist. Arthritis and Rheumatology, 2022, 74, 1102-1121.	5.6	14

#	Article	IF	CITATIONS
91	Pattern Recognition Receptors in Immune Disorders Affecting the Skin. Journal of Innate Immunity, 2012, 4, 225-240.	3.8	13
92	AL amyloidosis enhances development of amyloid A amyloidosis. British Journal of Dermatology, 2007, 156, 748-749.	1.5	12
93	The challenge of autoinflammatory syndromes: with an emphasis on hyper-lgD syndrome. Rheumatology, 2016, 55, ii23-ii29.	1.9	12
94	Optimal use of [18F]FDG-PET/CT in patients with fever or inflammation of unknown origin. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 51-58.	0.7	12
95	Blocking IL- $1\hat{l}^2$ to slow down progression of ALS?. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12741-12742.	7.1	11
96	Audiometric characteristics of a Dutch family with Muckle-Wells syndrome. Hearing Research, 2011, 282, 243-251.	2.0	11
97	Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet Journal of Rare Diseases, 2018, 13, 59.	2.7	11
98	Comment on: Schnitzlers syndrome exacerbation after anti-TNF treatment. Rheumatology, 2007, 46, 1741-1741.	1.9	7
99	Pseudonormalisation of the T wave: old wine?. Netherlands Heart Journal, 2007, 15, 257-259.	0.8	7
100	Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. Clinical and Experimental Medicine, 2009, 9, 291-296.	3.6	7
101	Evidence based recommendations for genetic diagnosis of Familial Mediterranean Fever. Pediatric Rheumatology, 2014, 12, .	2.1	7
102	Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 382-392.	3.8	7
103	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.1	5
104	International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors. Pediatric Rheumatology, 2015, 13, .	2.1	5
105	Genetic and phenotypic characteristics of $114\mathrm{patients}$ with mevalonate kinase deficiency. Pediatric Rheumatology, 2015, 13, .	2.1	5
106	Long chain fatty acid (Lcfa) abnormalities in hyper Igd syndrome (Hids) and familial Mediterranean fever (Fmf): New insight into heritable periodic fevers. Molecular Genetics and Metabolism, 2013, 108, 166-171.	1.1	4
107	FRIO488â€A Phase lii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 615.2-616.	0.9	4
108	Comment on "Power of Rare Diseases: Found in Translation― Science Translational Medicine, 2014, 6, 219le1.	12.4	3

#	Article	lF	CITATIONS
109	Anakinra Injection Site Reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-493.	1.3	3
110	Complex medical history of a patient with a compound heterozygous mutation inC1QC. Lupus, 2019, 28, 1255-1260.	1.6	3
111	Mevalonate kinase deficiency nomenclature. Rheumatology International, 2014, 34, 295-296.	3.0	2
112	FRIO489â€Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 616.1-616.	0.9	2
113	Familial Autoinflammatory Syndromes. , 2017, , 1666-1684.e4.		2
114	Response to Jolobe: †Molecular diagnostics in FUO†M. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 211-211.	0.5	2
115	Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology, 2022, 61, 2088-2094.	1.9	2
116	THU0570â€Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial. , 2018, , .		2
117	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39, 51-58.	0.8	2
118	Approach to the diagnosis of hereditary autoinflammatory syndromes. Future Rheumatology, 2007, 2, 5-8.	0.2	1
119	OR7-002 – Pyrin 577 mutations in dominant autoinflammation. Pediatric Rheumatology, 2013, 11, .	2.1	1
120	PW02-035 - A role for thermo-TRP channels in innate immunity?. Pediatric Rheumatology, 2013, 11, .	2.1	1
121	PW03-007 - NLRP3 genetic variants in Schnitzler's syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	1
122	A novel mutation in NLRC4 in a large pedigree with an anakinra responsive autoinflammatory disease. Pediatric Rheumatology, 2015, 13, P30.	2.1	1
123	THU0569â€Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 397.3-398.	0.9	1
124	Mevalonate Kinase Deficiency. , 2019, , 315-327.		1
125	Systemic Autoinflammatory Syndromes. , 2019, , 825-834.e1.		1
126	Familial Autoinflammatory Syndromes. , 2009, , 1863-1882.		1

#	Article	IF	Citations
127	Response to "Schnitzler's Syndrome: A True Auto-Inflammatory Disorder?― Seminars in Arthritis and Rheumatism, 2008, 38, 164.	3.4	0
128	OR5-002 – In vitro studies in Schnitzler's syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	0
129	PW02-034 - NLRP3 mosaicism detection in CAPS using NGS. Pediatric Rheumatology, 2013, 11, .	2.1	0
130	OR11-002 - Mutations in MVK cause non-syndromic RP. Pediatric Rheumatology, 2013, 11, .	2.1	0
131	PW03-006 - IL-1-B inhibition in Schnitzler's syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	O
132	THU0377â€Efficacy, safety and pharmacokinetics of the anti-interleukin-1 beta antibody canakinumab in patients with schnitzler syndrome. Annals of the Rheumatic Diseases, 2013, 71, 283.1-283.	0.9	0
133	OP0175â€The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years. Annals of the Rheumatic Diseases, 2013, 71, 114.1-114.	0.9	0
134	Evidence based recommendations for diagnosis and treatment of tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS). Pediatric Rheumatology, 2014, 12, .	2.1	0
135	Evidence based recommendations for diagnosis and management of mevalonate kinase defiency (MKD). Pediatric Rheumatology, 2014, 12, .	2.1	O
136	The Concept of Autoinflammatory Diseases. , 2014, , 39-50.		0
137	Successful kidney transplantation during anakinra treatment without complications. Pediatric Rheumatology, 2015, 13, .	2.1	0
138	OP0254â€CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER). , 2019, , .		0
139	Familial Autoinflammatory Syndromes. , 2013, , 1597-1615.e4.		O
140	Systemic autoinflammatory syndromes. , 2013, , 728-739.		0
141	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 51-58.	0.8	0